$8.72
$11.41
52-Week Range
At a Glance
AI-generatedHaleon plc reported FY 2025 revenue of $11.03B, down 1.8% YoY from $11.23B, primarily due to FX headwinds of 2.8% and net M&A impact of 2.0%, offset by 3.0% organic growth.
6-K
Haleon plc announced the purchase of 8,939,706 ordinary shares for cancellation under its share buyback program, resulting in 8,920,282,600 ordinary shares with voting rights as of 30 March 2026.$44.3B
Market Cap
$4.0B
Revenue
$552M
Net Income
Employees24,561
Fundamentals
How The Business Makes Money
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Industry Drug Manufacturers - Specialty & Generic
Activity
What Changed Recently
Company Profile
CIK0001900304
ISINUS4055521003
CUSIP405552100
Phone44 1932 822000
AddressBuilding 5, Weybridge, KT13 0NY, GB
SEC EDGAR